StockNews.AI
UNCY
StockNews.AI
36 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

1. Pomerantz LLP investigates claims against Unicycive for potential securities fraud. 2. Unicycive received a Complete Response Letter from the FDA regarding OLC. 3. Stock price dropped by 29.85%, closing at $4.77 after FDA announcement. 4. Investors are advised to contact Pomerantz for potential class action participation. 5. FDA cited manufacturing vendor for deficiencies impacting Unicycive's application.

4m saved
Insight
Article

FAQ

Why Very Bearish?

The stock crashed nearly 30% due to FDA's negative response, similar to other companies facing CRLs.

How important is it?

The investigation and FDA actions significantly undermine investor confidence, leading to potential losses.

Why Short Term?

Immediate negative market reaction, but potential for recovery if issues are resolved.

Related Companies

FGENAMGNVRTX
NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Unicycive and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On June 30, 2025, Unicycive release issued a press release “announc[ing] that the U.S. Food and Drug Administration (FDA) has issued a CRL [Complete Response Letter] for its New Drug Application (NDA) for OLC to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis.” The press release stated that “[a]fter submitting the NDA, and as a part of the application review and routine information requests, the FDA notified Unicycive that a third-party manufacturing vendor of its main contract development and manufacturing organization (CDMO) was cited for deficiencies following a cGMP inspection.” On this news, Unicycive’s stock price fell $2.03 per share, or 29.85%, to close at $4.77 per share on June 30, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980

Related News